玻璃体内注射贝伐单抗治疗脉络膜骨瘤相关脉络膜新生血管的长期疗效。
Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma.
作者信息
Yoshikawa Tadanobu, Takahashi Kanji
机构信息
Department of Ophthalmology, Kansai Medical University, Osaka, Japan.
出版信息
Clin Ophthalmol. 2015 Mar 3;9:429-37. doi: 10.2147/OPTH.S78817. eCollection 2015.
PURPOSE
To describe the outcomes of intravitreal injections of bevacizumab for choroidal neovascularization (CNV) associated with choroidal osteoma.
METHODS
Retrospective consecutive case series. Three eyes of three patients were studied. All patients were treated with intravitreal injections of bevacizumab for CNV associated with choroidal osteoma. Best-corrected visual acuity, central foveal thickness, tumor thickness on spectral domain optical coherence tomography, and subretinal pigmentation around the CNV were evaluated.
RESULTS
The mean number of intravitreal injections of bevacizumab was 2.0 (range 1-3). The mean follow-up time was 56.0 months (range 25-99 months). The mean LogMAR visual acuity worsened from 0.1 to 0.6. LogMAR visual acuity loss of 0.7 or worse occurred in two of three eyes. CNV was located in the subfoveal area in two eyes, and CNV was located in the juxtafoveal area in one eye. The mean central foveal thickness decreased from 407 μm to 251 μm. The mean tumor thickness decreased from 709 μm to 608 μm. All eyes had subretinal pigmentation around the CNV.
CONCLUSION
Intravitreal injections of bevacizumab for subfoveal CNV associated with decalcified choroidal osteoma resulted in poor visual acuity.
目的
描述玻璃体内注射贝伐单抗治疗与脉络膜骨瘤相关的脉络膜新生血管（CNV）的结果。
方法
回顾性连续病例系列。研究了3例患者的3只眼。所有患者均接受玻璃体内注射贝伐单抗治疗与脉络膜骨瘤相关的CNV。评估最佳矫正视力、中心凹厚度、光谱域光学相干断层扫描上的肿瘤厚度以及CNV周围的视网膜下色素沉着。
结果
玻璃体内注射贝伐单抗的平均次数为2.0次（范围1 - 3次）。平均随访时间为56.0个月（范围25 - 99个月）。平均LogMAR视力从0.1恶化至0.6。三只眼中有两只眼的LogMAR视力损失达到或超过0.7。两只眼的CNV位于黄斑中心凹下区域，一只眼的CNV位于黄斑旁区域。平均中心凹厚度从407μm降至251μm。平均肿瘤厚度从709μm降至608μm。所有眼睛的CNV周围均有视网膜下色素沉着。
结论
玻璃体内注射贝伐单抗治疗与脱钙脉络膜骨瘤相关的黄斑中心凹下CNV导致视力不佳。
Zotero 插件